PMID- 26682842
OWN - NLM
STAT- MEDLINE
DCOM- 20160916
LR  - 20240327
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2015
DP  - 2015 Dec 18
TI  - Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal 
      vasculopathy.
LID - 10.1136/bcr-2015-212988 [doi]
LID - bcr2015212988
AB  - Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually 
      treated using photodynamic therapy (PDT) and antivascular endothelial growth 
      factor agents. However, these cases may sometimes be refractory to both PDT and 
      ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. 
      Recently, studies have reported that aflibercept may be effective in such 
      resistant cases. However, high cost and limited availability has restricted its 
      use to only a few countries. Ziv-aflibercept (Zaltrap), a systemic analogue of 
      aflibercept, has been tried recently and it has been effective in macular oedema. 
      We report a case of PCV resistant to PDT and ranibizumab, which responded well to 
      intravitreal ziv-aflibercept.
CI  - 2015 BMJ Publishing Group Ltd.
FAU - Videkar, Chetan
AU  - Videkar C
AD  - Department of Retina, LV Prasad Eye Institute, Hyderabad, Telangana, India.
FAU - Kapoor, Aditya
AU  - Kapoor A
AD  - Department of Retina, LV Prasad Eye Institute, Hyderabad, Telangana, India.
FAU - Chhablani, Jay
AU  - Chhablani J
AD  - LV Prasad Eye Institute, Hyderabad, Telangana, India.
FAU - Narayanan, Raja
AU  - Narayanan R
AD  - Department of Retina, LV Prasad Eye Institute, Hyderabad, Telangana, India.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20151218
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Immunologic Factors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Choroid/blood supply
MH  - Choroid Diseases/*drug therapy
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Intravitreal Injections
MH  - Male
MH  - Peripheral Vascular Diseases/*drug therapy
MH  - Ranibizumab/therapeutic use
MH  - Receptors, Vascular Endothelial Growth Factor/*administration & dosage
MH  - Recombinant Fusion Proteins/*administration & dosage
PMC - PMC4691871
EDAT- 2015/12/20 06:00
MHDA- 2016/09/17 06:00
PMCR- 2017/12/18
CRDT- 2015/12/20 06:00
PHST- 2015/12/20 06:00 [entrez]
PHST- 2015/12/20 06:00 [pubmed]
PHST- 2016/09/17 06:00 [medline]
PHST- 2017/12/18 00:00 [pmc-release]
AID - bcr-2015-212988 [pii]
AID - 10.1136/bcr-2015-212988 [doi]
PST - epublish
SO  - BMJ Case Rep. 2015 Dec 18;2015:bcr2015212988. doi: 10.1136/bcr-2015-212988.